North Carolina Doctors Sought Arthritis Care Reform
Rheumatologists urged federal lawmakers to address insurance hurdles impacting patient access to treatment.
Updated on Oct. 8, 2026 in Arthritis
Live Poll
Should federal law place stricter limits on how insurance companies manage patient treatment approvals?
The North Carolina Rheumatology Association met with federal lawmakers in Washington, D.C., to lobby for changes to pharmacy benefit management and insurance protocols. These policies currently dictate how patients access essential arthritis medications.
Why it matters
Prior authorization and step therapy requirements, alongside reimbursement issues for biosimilars, often prevent patients from receiving doctor-prescribed treatments. These financial barriers have forced some North Carolina clinics to stop offering necessary infusions, shifting patient care to higher-cost hospital outpatient settings.
A North Carolina Rheumatology Association delegation addressed four distinct medical access policies during recent federal meetings. The long-term impact on insurance reimbursement rates for complex medications remains under investigation.
The players
North Carolina Rheumatology Association
A professional group representing specialists in the diagnosis and management of arthritis and autoimmune conditions.
The details
Insurance protocols like step therapy require patients to try lower-cost medications before accessing specialized treatments, regardless of physician preference. Simultaneously, if clinics face acquisition costs for drugs that exceed reimbursement rates, they may discontinue those services to avoid financial loss. When clinics cease these infusions, patients are often forced into hospital-based settings, which frequently charge additional facility fees that increase the overall cost of chronic care.
Timeline
October 8, 2026: The advocacy delegation meeting occurred in Washington, D.C.
Health Landscape
This advocacy effort follows the pattern of ongoing national pressure to update the Pharmacy Benefit Manager Reform Act to curb high drug costs. It highlights the growing tension between clinic-based care access and current pharmacy benefit management structures.
If you struggle with access to prescribed arthritis medications due to insurance or pharmacy policies, it is worth discussing these hurdles with your physician. They can document the clinical necessity of your treatment and help you explore available pathways within current coverage systems.
The takeaway
Insurance reimbursement challenges can limit where you receive treatment, often forcing patients out of local clinics and into expensive hospital settings. If your treatment site changes, ask your healthcare provider about how facility fees might affect your out-of-pocket costs.
Further reading
For more information on managing your care, visit the Arthritis resources page.
Source note: This article includes information reported by Public Radio East.
Live Poll
Should federal law place stricter limits on how insurance companies manage patient treatment approvals?
